Skip to content
Peptide research

Melanotan I

Also known as Afamelanotide · Scenesse · CUV1647 · NDP-MSH
Category
Skin & Cosmetic
Administration routes
Injectable
Regulatory status
FDA-approved

A linear alpha-MSH analog that binds MC1R to raise eumelanin, sold as an approved implant and also used, outside its approval, for cosmetic tanning. Evidence for EPP photoprotection is solid; quality-of-life and vitiligo gains are moderate; other claims are speculative. Skin darkening is expected, and nausea affected 19% in the FDA trial safety population. Moles need monitoring, and unregulated products carry melanoma case reports. Approved only for EPP; cosmetic tanning relies on unregulated products sold online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Scenesse (afamelanotide / Melanotan I) is a synthetic 13-amino-acid peptide that stimulates your skin to produce protective dark melanin (eumelanin) without UV exposure. Developed at the University of Arizona in the 1980s, it is FDA-approved (October 2019) as Scenesse for erythropoietic protoporphyria (EPP), a rare genetic condition causing extreme sun sensitivity and painful skin reactions to light. Unlike Melanotan II, which activates multiple melanocortin receptors and causes sexual and appetite side effects, Melanotan I selectively targets the MC1R receptor responsible for tanning.

How it works in the body

A linear analog of alpha-MSH that binds to MC1R receptors on melanocytes in the skin. This activates adenylyl cyclase, increasing cAMP levels, which drives the production of eumelanin (protective dark pigment). The result is skin darkening that provides some UV protection.

Research overview

Afamelanotide works by binding to the MC1R receptor on skin cells, shifting melanin production from the reddish, potentially damaging type (pheomelanin) to the brown, protective type (eumelanin). This also triggers antioxidant activity, DNA repair mechanisms, and anti-inflammatory signaling. Studies show it reduces sunburn cells by 50% and significantly decreases UV-induced DNA damage. It is delivered as a slow-release implant under the skin, with most of the drug released within 2 days and fully cleared by day 10. Beyond EPP, research has explored its potential for vitiligo, solar urticaria, and photoprotection in organ transplant patients, though these remain off-label uses.

Who researches Melanotan I?

Commonly researched by

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching photoprotection in epp

    One of the primary studied benefits of Melanotan I.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(9)

Rated by level of concern

  • Nausea and headache (very common, >10% of patients)

    Moderate

    FDA SCENESSE (afamelanotide) prescribing information, Adverse Reactions table

  • Implant site reactions including bruising and discomfort

    High

    FDA SCENESSE prescribing information (Adverse Reactions; Dosage and Administration)

  • Darkening of existing moles — requires regular dermatologic monitoring for melanocytic changes

    High

    FDA SCENESSE prescribing information, Warnings and Precautions (Skin Monitoring)

  • Diffuse skin hyperpigmentation experienced by nearly all patients

    High

    FDA SCENESSE prescribing information; PMID 33683075 ('nearly all patients experience diffuse hyperpigmentation')

  • Rare serious hypersensitivity reactions including anaphylaxis (post-marketing reports)

    Moderate

    Post-marketing hypersensitivity reports; FDA/EU SCENESSE safety labeling

  • New melanocytic nevi may develop during treatment

    Low

    FDA SCENESSE prescribing information, Adverse Reactions table

  • Unregulated melanotan products: 4 case reports of melanoma emergence, unknown purity/dosing, melanocytic changes in moles and dysplastic nevi

    Moderate

    PMID 28266027 (Habbema et al., Int J Dermatol 2017, including the explicit 'conclusive evidence... is lacking' caveat); PMID 28905366 (Adler et al., Australas J Dermatol 2017)

  • Safety not established in children, pregnancy/breastfeeding, or patients with liver/kidney impairment

    Moderate

    FDA SCENESSE prescribing information, Use in Specific Populations; PMID 33683075

  • Long-term effects of repeated eumelanin stimulation beyond clinical trial durations not fully characterized

    Theoretical

    PMID 28063031 (Clin Pharmacokinet 2017, 25-year safety observation); PMID 33683075

Interaction summary(8)

Rated by direction with this peptide

  • Narrowband UV-B phototherapy

    SynergisticModerate

    Combining afamelanotide implants with NB-UVB produced greater and faster repigmentation in vitiligo than NB-UVB alone (48.6% vs 33.3% at day 168) in a randomized multicenter trial, replicated in a randomized trial in Asian patients. The pivotal trial was open-label, and the combination darkens uninvolved skin, increasing contrast in darker phototypes.

    PMID 25230094 (JAMA Dermatol 2015, open-label RCT); PMID 31987791 (J Am Acad Dermatol 2020)

  • Sun-protective measures (sunscreen, clothing, UV avoidance)

    ProtectiveLow

    Afamelanotide is an adjunct, not a replacement: induced tanning provides only partial UV protection, and patients should maintain standard photoprotection and continue routine skin surveillance during therapy.

    FDA SCENESSE prescribing information (Skin Monitoring); PMID 28266027

  • Intentional UV exposure / tanning beds

    CautionLow

    Behavioral rather than pharmacologic: cosmetic darkening can create a false sense of protection and encourage additional UV exposure, a concern raised in reviews of unregulated melanotan use within tanning culture. No clinical study has quantified the resulting risk.

    PMID 28266027 (Habbema et al., Int J Dermatol 2017)

  • Other melanocortin analogues (melanotan-II, bremelanotide, unregulated tanning peptides)

    CautionModerate

    Using more than one MC1R agonist adds no established benefit while compounding pigmentary, gastrointestinal and melanocytic-lesion effects, and illicit products carry unknown purity and dosing; melanotan-II is less selective (MC3R/MC4R activity) and has case-report associations with nausea, flushing and priapism. Evidence is case-report/review level, not comparative trial data.

    PMID 28266027; PMID 28905366

  • Anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)

    CautionTheoretical

    There is no pharmacologic interaction and no interaction data. The label identifies implant site reaction generally — not bruising or hematoma specifically — as the most common adverse event. The practical point is procedural: the implant is inserted subcutaneously, so insertion technique and bleeding risk deserve attention in anticoagulated patients.

    FDA SCENESSE prescribing information (Dosage and Administration; Adverse Reactions) — extrapolation, no interaction studies performed

  • Systemic immunosuppressants / organ transplant recipients

    CautionTheoretical

    In patients already at elevated skin-cancer risk, drug-induced hyperpigmentation may obscure clinical detection of melanocytic lesions; no interaction or outcome data exist in this population, and dermatologic surveillance should be intensified.

    Mechanism plus FDA SCENESSE skin-monitoring warning (no clinical interaction studies performed)

  • CYP450-metabolized drugs (general co-medication)

    NeutralLow

    Afamelanotide is a 13-amino-acid peptide cleared by peptidase hydrolysis with no CYP-mediated metabolism, and no formal drug-drug interaction studies are described in the label; clinically meaningful pharmacokinetic interactions are not expected.

    PMID 28063031 (Clin Pharmacokinet 2017 PK/PD review); FDA SCENESSE prescribing information

  • Photosensitizing drugs (tetracyclines, thiazides, amiodarone, voriconazole, NSAIDs)

    CautionTheoretical

    No studied interaction, but drug-induced photosensitivity can offset the partial photoprotection afamelanotide provides in EPP and other photodermatoses; review medication lists before attributing breakthrough phototoxicity to treatment failure.

    Mechanism-based; no interaction data in FDA SCENESSE labeling

Known risks(9)

  • Nausea and headache (very common, >10% of patients)

  • Implant site reactions including bruising and discomfort

  • Darkening of existing moles — requires regular dermatologic monitoring for melanocytic changes

  • Diffuse skin hyperpigmentation experienced by nearly all patients

  • Rare serious hypersensitivity reactions including anaphylaxis (post-marketing reports)

  • New melanocytic nevi may develop during treatment

  • Unregulated melanotan products: 4 case reports of melanoma emergence, unknown purity/dosing, melanocytic changes in moles and dysplastic nevi

  • Safety not established in children, pregnancy/breastfeeding, or patients with liver/kidney impairment

  • Long-term effects of repeated eumelanin stimulation beyond clinical trial durations not fully characterized

Drug interactions(4)

  • Anticoagulants / blood thinners

    Patients on blood thinning medication may experience increased bruising or bleeding at implant insertion site due to subcutaneous administration method.

  • Photosensitizing medications

    Drugs causing photosensitivity (tetracyclines, fluoroquinolones, NSAIDs, thiazides) may have altered effects when combined with afamelanotide-induced melanin changes. No formal interaction studies conducted.

  • Other melanocortin receptor agonists

    Using it with melanotan II or other MC receptor agonists could cause excessive melanocortin receptor stimulation; avoid concurrent use.

  • Hepatically/renally cleared drugs

    Metabolism and distribution of afamelanotide not fully characterized as of 2017. Caution in patients with liver or kidney impairment; contraindicated in those populations.

Research & benefits

Evidence base

Evidence Level
Level 1 — FDA Approved
Total Studies
20
Human Studies
10

Two pivotal Phase III multicenter, randomized, double-blind, placebo-controlled trials (168 patients total: 74 EU, 94 US). Additional Phase II/III trials in vitiligo, polymorphic light eruption, and other photodermatoses. FDA approval based on 3 trials totaling 244 adults across 22 US and European sites. Post-marketing observational data from 200-patient German cohort confirms long-term safety.

Researched for(8)

Rated by confidence in the evidence

  • Photoprotection in EPP

    High

    Two blinded, placebo-controlled trials enrolled 168 patients: 74 in the EU and 94 in the US.

    PMID 26132941 (Langendonk et al., N Engl J Med 2015;373:48-59); FDA SCENESSE prescribing information

  • Eumelanin production without UV

    High

    Skin darkening was recorded as a trial-confirmed effect in vehicle-controlled human studies, without UV exposure.

    FDA SCENESSE prescribing information (Adverse Reactions); PMID 28063031 (Minder et al., Clin Pharmacokinet 2017 PK/PD review)

  • Quality of life improvement in EPP

    Medium

    Quality-of-life gains were a secondary endpoint in RCTs, with further support from a retrospective cohort study.

    PMID 26132941 (secondary endpoint); PMID 36244556 (J Am Acad Dermatol 2023, retrospective cohort)

  • DNA repair enhancement

    Speculative

    DNA-repair responses have been investigated in a small human mechanistic study; sponsor-reported biopsy findings remain preliminary.

    PMID 28063031 (review states afamelanotide 'enhances DNA repair processes'); in vitro melanocyte literature

  • Anti-inflammatory photoprotection

    Low

    Anti-inflammatory effects are established in cell and animal studies, but not isolated in human trials.

    PMID 28063031; PMID 33683075 (Wu & Cotliar, J Drugs Dermatol 2021)

  • Potential vitiligo treatment

    Medium

    Open-label randomized trials with NB-UVB showed modest repigmentation gains over UVB alone, unblinded and off-label.

    PMID 25230094 (Lim et al., JAMA Dermatol 2015;151:42-50, open-label RCT); PMID 31987791 (J Am Acad Dermatol 2020, vitiligo in Asians)

  • Polymorphic light eruption prevention

    Low

    A review cites RCT evidence for this use, but no primary trial report could be verified.

    PMID 33683075 (J Drugs Dermatol 2021, cites but does not reproduce RCT evidence for PLE); PMID 28063031 (lists PLE among clinical applications)

  • Broad photodermatosis applications

    Low

    Small pilot trials suggest possible benefit for polymorphic light eruption and solar urticaria.

    PMID 30517779 (McNeil et al., Skin Therapy Lett 2018); PMID 33683075 (J Drugs Dermatol 2021) reviews of afamelanotide, which is Melanotan I itself (same molecule, [Nle4,D-Phe7]-alpha-MSH), not a separate related compound

Benefits(8)

  • Photoprotection in EPP

  • Eumelanin production without UV

  • Quality of life improvement in EPP

  • DNA repair enhancement

  • Anti-inflammatory photoprotection

  • Potential vitiligo treatment

  • Polymorphic light eruption prevention

  • Broad photodermatosis applications

Key studies(6)

  1. Afamelanotide for Erythropoietic Protoporphyria

    Phase III RCT (double-blind, placebo-controlled)168 patients (74 EU + 94 US)6 months in the US trial; 9 months in the EU trial

    Langendonk JG, Balwani M, Anderson KE, et al.

    New England Journal of Medicine

    2015

    Afamelanotide was associated with increased duration of sun exposure without pain and improved quality of life in EPP patients. Well tolerated with no drug-related serious adverse events.

  2. Homey B, Schelonke K, Schlegel CM, et al.

    Photodermatology, Photoimmunology & Photomedicine

    2025

    Long-term safety profile consistent with clinical trials. Significant QoL improvement (p < 0.0001). 91% treatment continuation rate. Safe across age groups including patients over 70.

  3. Wensink D, Wagenmakers MAEM, Langendonk JG

    Expert Review of Clinical Pharmacology

    2021

    First effective approved treatment for EPP. Clinical effectiveness appears greater in practice than trial data suggested. Current dosing intervals may be insufficient for some patients. Common adverse events: headache, fatigue, nausea.

  4. Leaf RK, Naik H, Jiang PY, et al.

    Life (Basel)

    2024

    Median time to symptom onset increased from 12.5 to 120 minutes after treatment. Significant QoL improvements and reduced depression. No improvement in protoporphyrin levels, indicating benefits operate through photoprotective mechanisms rather than reducing porphyrin accumulation.

  5. Wu J, Cotliar R

    Journal of Drugs in Dermatology

    2021

    Beyond EPP, afamelanotide shows promise in vitiligo (RCT data), polymorphic light eruption, acne vulgaris, Hailey-Hailey disease, and solar urticaria. Dual photoprotective and anti-inflammatory properties. No serious adverse effects reported.

  6. Habbema L, Halk AB, Neumann M, Bergman W

    International Journal of Dermatology

    2017

    Unregulated melanotan products pose risks including melanocytic changes in moles and newly emerging dysplastic nevi. Four case reports of melanomas emerging during/after melanotan use. Afamelanotide is the only thoroughly tested and approved α-MSH analog.

What research suggests over time

  • Weeks 2-4

    FDA-approved (Scenesse)

    Afamelanotide exposure occurs over days after implantation; the pigmentation effect lasts longer than measurable plasma exposure.

  • Months 2-3

    Phase 3 RCT

    Dramatic reduction in EPP photosensitivity reactions; significant increase in pain-free sun exposure duration vs placebo (NEJM 2015).

  • Long-term

    Phase 3 + LTFU

    Sustained protection with quarterly implants; 91% treatment continuation rate; significant QoL improvement (p<0.0001) in long-term safety follow-up (Photodermatology 2025).

Prescribing labels

FDA-Approved Labels

This page does not list doses. Each product below has an FDA label with its prescribing information.

Protocol
Scenesse (afamelanotide)
Notes
Dosing is set by your prescriber and the FDA label.

Monitoring & labs

Baseline before starting, then per marker schedule during protocol.

Baseline labs(4)

  • Complete Blood Count (CBC)

    Optimal All markers within mid-range

    Establishes baseline for detecting hematological changes.

    Lab normal Standard reference ranges

  • Comprehensive Metabolic Panel (CMP)

    Optimal Liver enzymes <25, glucose 75–90, eGFR >90

    Liver and kidney function baseline.

    Lab normal Standard reference ranges

  • C-Reactive Protein (CRP)

    Optimal Under 1.0 mg/L

    Baseline inflammatory marker relevant to skin conditions.

    Lab normal Under 3.0 mg/L

  • Dermatologic screening (mole mapping)

    Baseline skin assessment — melanocyte-stimulating peptide with documented melanoma concern.

Ongoing tracking(3)

  • Liver enzymes (ALT/AST)

    Every 8 weeksOptimal ALT & AST under 25 U/L

    Hepatic monitoring for injectable protocols.

    Lab normal ALT 7–56, AST 10–40 U/L

  • CRP

    Every 8 weeksOptimal Under 1.0 mg/L

    Track inflammatory skin markers.

    Lab normal Under 3.0 mg/L

  • Dermatologic check

    Every 12 weeks

    Monitor for new or changing moles — melanocyte-stimulating peptide.

Retest schedule(5)

  1. Baseline

    critical

    Before starting

    Full baseline panel — establish reference values for all monitored markers.

  2. Early follow-up

    critical

    Week 4-6

    Spot-check for early changes — focus on glucose, liver enzymes, and any peptide-specific markers.

  3. Mid-protocol

    critical

    Week 12

    Comprehensive retest. Compare all markers to baseline.

  4. Ongoing

    standard

    Quarterly

    Continued monitoring during extended protocols.

  5. Post-protocol

    standard

    4-6 weeks after stopping

    Confirm return to baseline. Important for GH and metabolic peptides.

When to stop and reassess(4)

  • ALT or AST

    stop

    Above 2× upper limit of normal (>~80 U/L)

    Stop protocol and consult a provider — possible drug-induced liver injury.

  • eGFR

    stop

    Drop of >15 mL/min/1.73m² from baseline, or below 60

    Stop protocol and consult a provider — possible kidney function decline.

  • Symptoms

    stop

    New severe symptoms correlating with lab changes

    Stop protocol and seek medical evaluation immediately.

  • Skin lesions

    stop

    Any new or changing mole

    Stop protocol and consult a dermatologist — melanocyte-stimulating peptide.

Lab monitoring helps track your body's response to Melanotan I. Any unexplained changes should prompt discussion with your prescribing provider.

Regulation & availability

Why researchers look at it

Clinical studies showed a 50% reduction in sunburn cells and significant decrease in UV-induced DNA damage, with treated patients going from tolerating 12 minutes of sunlight to 2 hours pain-free. Trials in vitiligo and photoprotection for transplant patients at elevated skin cancer risk could expand it well beyond its current rare-disease approval.

Estimated cost
$2,000-5,000/treatment (Scenesse implant); limited availability
FDA status
FDA-approved (October 8, 2019). Brand name: Scenesse. NDA 210797. Designated first-in-class medication. Orphan drug designation: US July 17, 2008; EU May 8, 2008. Approved indication: increasing pain-free light exposure in adult patients with erythropoietic protoporphyria (EPP). Approval based on three clinical trials with 244 adults across 22 sites. No FDA REMS was required. EMA approved December 2014. Italy provided reimbursed early access under Law 648/1996 from May 2010.
WADA status
Afamelanotide is not named on the WADA 2026 Prohibited List and has approval for human therapeutic use. S0 is determined by substance approval, not whether a prescription is for an approved indication. A mandatory TUE requirement for Scenesse has not been established; athletes should obtain a product-specific determination from their anti-doping organization. Melanotan II is a different substance.
Prescribability
FDA-approved prescription drug (Scenesse) for EPP, given as a subcutaneous implant by healthcare professionals only. Available through specialty pharmacies and certified treatment centers. Unregulated 'melanotan' products sold online are not the same as the approved pharmaceutical product.
Availability
FDA-approved as Scenesse (subcutaneous implant) since October 2019. EMA-approved since December 2014. Australian TGA approved October 2020. Available only through certified healthcare providers and specialty pharmacies for diagnosed EPP patients. Must be administered by a healthcare professional. Expiration of orphan exclusivity on October 8, 2026 does not establish a generic launch date; patent and approval requirements also matter. Unregulated 'melanotan' products are widely sold online but are not equivalent to the approved pharmaceutical product and carry significant safety risks.

International status

  • EU

    EMA-approved (Scenesse) for EPP

  • US

    FDA-approved (Scenesse) for EPP only

  • Australia

    TGA-approved (Scenesse)

Regulatory timeline(10)

  1. 1980s
    Synthesis at University of ArizonaAfamelanotide synthesized as one of several potent α-MSH analogs by researchers at the University of Arizona.
  2. 2004
    Depot formulation developedSubcutaneous implant formulation enabling controlled slow-release delivery developed.
  3. 2006
    Epitan renamed to Clinuvel PharmaceuticalsDevelopment company rebranded as Clinuvel Pharmaceuticals Ltd.
  4. 2007
    Health agency warnings beginMultiple national health organizations begin issuing safety warnings about unregulated melanotan products.
  5. 2010-05
    Italian early access (AIFA)Italian reimbursed early access: AIFA provides access to afamelanotide for EPP under Law 648/1996.
  6. 2008
    Orphan drug designation (US and EU)Orphan drug designation for EPP: EU May 8, 2008; US July 17, 2008.
  7. 2014-12
    EMA approval (EU)European Medicines Agency grants marketing authorization for Scenesse for EPP in adults.
  8. 2019-10-08
    FDA approval (US)FDA approves Scenesse (NDA 210797) for increasing pain-free light exposure in adult EPP patients. Designated first-in-class. Based on 3 trials with 244 adults.
  9. 2020-10
    TGA approval (Australia)Australian Therapeutic Goods Administration approves afamelanotide for EPP.
  10. 2026-10-08
    Orphan exclusivity expiresThis date alone does not establish generic approval eligibility or market entry; patent requirements also apply.

Sources & FAQs

Research sources(9)

Frequently asked questions(6)

What is the difference between Melanotan I and Melanotan II?

Melanotan I (afamelanotide) is a linear 13-amino-acid peptide selective for the MC1R receptor, FDA-approved as Scenesse for EPP. Melanotan II is a shorter cyclic 7-amino-acid peptide that acts on multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R), causing tanning plus sexual arousal, appetite suppression, and other effects. Melanotan II is NOT approved by any regulatory agency and carries greater side effect risks.

Is Melanotan I FDA-approved?

Yes. Afamelanotide (Scenesse) was FDA-approved on October 8, 2019, for increasing pain-free light exposure in adult patients with erythropoietic protoporphyria (EPP). It is designated as a first-in-class medication. It received EU marketing authorization on December 22, 2014, and Australian approval on October 26, 2020, followed by registration on November 18, 2020.

Can I use Melanotan I just for tanning?

The FDA-approved product (Scenesse) is only prescribed for EPP. Multiple national health agencies have issued warnings against this practice.

How is Scenesse administered?

Scenesse is a biodegradable implant (about 1.7 cm long) inserted subcutaneously near the hip by a healthcare professional, timed before periods of expected sun exposure. Dosing is set by your prescriber and the FDA label.

Does Melanotan I cause melanoma?

In clinical trials and post-marketing surveillance of the approved product (Scenesse), no evidence links afamelanotide to increased melanoma risk. However, unregulated melanotan products have been associated with 4 case reports of melanomas emerging from existing moles. Afamelanotide darkens existing moles, making dermatologic monitoring important.

What are the most common side effects?

Very common (>10%): nausea and headache. Common (1-10%): implant site reactions, back pain, upper respiratory infections, darkening of existing moles (melanocytic nevi), fatigue, dizziness, and mild skin changes. Most side effects resolve within 72 hours. Rare cases of hypersensitivity including anaphylaxis reported post-marketing.